Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma

Leukemia volume 18, pages 659–662 (2004)Cite this article

TO THE EDITOR

Allogeneic stem cell transplantation may hold the potential of curing multiple myeloma (MM). Despite high treatment-related mortality of 17–40%,1 lower relapse rates in comparison to autologous transplantation have been reported, probably due to a graft-versus-myeloma effect exerted by immunocompetent donor lymphocytes.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Gahrton G, Svensson H, Cavo M, Apperly J, Bacigalupo A, Bjorkstrand B et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001; 113: 209–216.

    Article  CAS  Google Scholar 

  2. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631–637.

    Article  CAS  Google Scholar 

  3. Kroger N, Schwerdtfeger R, Kiehl M, Sayer HG, Renges H, Zabelina T et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002; 100: 755–760.

    Article  CAS  Google Scholar 

  4. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041–2050.

    CAS  PubMed  Google Scholar 

  5. Lokhorst HM, Schattenberg A, Cornelissen JJ, van Oers MH, Fibbe W, Russell I et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000; 18: 3031–3037.

    Article  CAS  Google Scholar 

  6. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B . Graft-versus-myeloma effect: proof of principle. Blood 1996; 87: 1196–1198.

    CAS  PubMed  Google Scholar 

  7. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261–1268.

    CAS  PubMed  Google Scholar 

  8. Dazzi F, Szydlo RM, Craddock C, Cross NC Kaeda J, Chase A et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000; 95: 67–71.

    CAS  PubMed  Google Scholar 

  9. Marks DI, Lush R, Cavenagh J, Milligan DW, Schey S, Parker A et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2002; 100: 3108–3114.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank the staff of the BMT units for providing excellent care of our patients and the medical technicians for their excellent work in the BMT laboratories. This work was supported by a grant of the Roggenbuck-Foundation and the Deutsche Krebshilfe (70-3133-Kr I).

Author information

Authors and Affiliations

  1. Department of Bone Marrow Transplantation, University Hospital Hamburg-Eppendorf, Germany

    F Ayuk, T Zabelina, A R Zander & N Kröger

  2. Department of Oncology and Haematology, Chaim Sheba Medical Center, Tel Hashomer, Israel

    A Shimoni & A Nagler

  3. Department of Bone Marrow Transplantation, DKD-Clinic, Wiesbaden, Germany

    R Schwerdtfeger

  4. Bone Marrow Transplantation Clinic, Idar-Oberstein, Germany

    M Kiehl

  5. Department of Oncology and Haematology, University of Jena, Germany

    H G Sayer

Authors
  1. F Ayuk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Shimoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Nagler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Schwerdtfeger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Kiehl
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H G Sayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T Zabelina
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A R Zander
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. N Kröger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N Kröger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ayuk, F., Shimoni, A., Nagler, A. et al. Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma. Leukemia 18, 659–662 (2004). https://doi.org/10.1038/sj.leu.2403252

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403252

This article is cited by

Search

Advanced search

Quick links